Ranked as one of the Top 50 Fastest Growing Private Companies in Massachusetts
Veristat Strengthens its Clinical Operations, Medical and Regulatory Affairs Offerings
SOUTHBOROUGH, MA – November 07, 2016 – Veristat announced that it has appointed James (Jim) Roach, MD, FACP, FCCP as its new Chief Medical Officer to bolster the expansion of its clinical operations, medical and regulatory affairs offerings.
SOUTHBOROUGH, MA – November 01, 2016 – Veristat, a full service consultative Clinical Research Organization (CRO), announced today the formal launch of its Strategic Decision Consulting service offering to help pharmaceutical, biotechnology and medical device firms solve the unique and complex challenges they face throughout the development process.
Veristat, a full service Clinical Research Organization (CRO), announced today the signing of a Preferred Provider Agreement (PPA) with Aegerion Pharmaceuticals Inc. (“Aegerion”), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. Veristat has assisted Aegerion with US Food and Drug Administration, EU Market Authorization Application, and Japan Food and Drug Administration submission projects over the past 5 years.
Veristat Continues To Be Recognized for Its Positive Impact & Company Growth
SOUTHBOROUGH, MA – August 17, 2016 – Veristat announced today that it has been recognized once again by Inc. Magazine as one of America’s fastest-growing private companies. Veristat debuted on the list in 2015.
Accelerates Hiring & Plans to Open Office in Raleigh-Durham, North Carolina
Appoints Mark Chang as Senior Vice President of Strategic Statistical Consulting
SOUTHBOROUGH, MA – June 15, 2016 – Veristat, a full service Clinical Research Organization (CRO), announced that it has strengthened its statistical consulting and adaptive design expertise with the appointment of Mark Chang, PhD to the newly created position of Senior Vice President of Strategic Statistical Consulting. Dr. Chang will help clients evaluate and implement strategic, operational and technical efficiencies to advance products through the clinical trial and regulatory submission process.
SOUTHBOROUGH, MA – May 2, 2016 – Veristat, a full service Clinical Research Organization (CRO), announced today that it is expanding its clinical research offerings into Europe through the acquisition of UK-based CRO, Spero Oncology. Spero Oncology is a UK-based CRO specializing in providing clinical operations support for oncology clinical trials primarily throughout Europe, but also in Australia and New Zealand. With the acquisition of Spero Oncology, Veristat now offers its clients full clinical operations support in Europe including feasibility studies, legal representation in the European Union, Clinical Monitoring, Project Management, Protocol Writing and Regulatory Strategy.